ChloroquineV1, Istex, Corpus, bibRecord, 001895

Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis

Identifieur interne : 001895 ( Istex/Corpus ); précédent : 001894; suivant : 001896

Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis

Auteurs : O. Vittecoq ; F. Jouen-Beades ; K. Krzanowska ; I. Bichon-Tauvel ; J. F. Menard ; A. Daragon ; D. Gilbert ; F. Tron ; X. Le Loe T

Source :

Rheumatology [ 1462-0324 ] ; 2000.

RBID : ISTEX:0A72297B4B08314DD6A093A83221189C1CDE470D

Abstract

Objectives. To evaluate the frequencies of antineutrophil cytoplasmic (ANCA), anticardiolipin (aCLA) and anti‐β2‐glycoprotein 1 antibodies (aβ2‐GP1A) in rheumatoid arthritis (RA) of limited duration in patients recruited primarily from private practitioners (80%), and to attempt to correlate the presence of these antibodies with certain clinical and/or biological criteria. Patients and methods. Patients (n = 102) with RA evolving for <5 yr (mean 2.2 yr) were recruited. A home evaluation collected clinical data [Ritchie articular index, Health Assessment Questionnaire (HAQ) index, extra‐articular manifestations] and blood for biological analyses [C‐reactive protein (CRP), rheumatoid factor, ANCA, aCLA, aβ2‐GP1A]. ANCA were detected by indirect immunofluorescence on neutrophils and their specificity was determined by enzyme‐linked immunosorbent assay (ELISA) and confirmed by immunoblotting; aCLA and aβ2‐GP1A were detected by ELISA. Results. Patients had mild RA (Ritchie = 11/78 ± 9.6; HAQ = 0.79/3 ± 0.7), probably due to the recruitment procedure. ANCA, aCLA and aβ2‐GP1A frequencies were 18.5, 7 and 0%, respectively. Titres of ANCA and aCLA were low. A perinuclear ANCA staining pattern was exclusively observed and lactoferrin was shown to be the major antigen recognized. No relationship was found between ANCA and aCLA and/or rheumatoid factor, or any clinical manifestations. ANCA were more common in RA of longer duration (cut‐off: 4 yr; P = 0.05) and aCLA were correlated with the CRP level (P = 0.05). Conclusions. In RA of recent onset, ANCA and aCLA were detected at low titres and frequencies, and were not associated with any clinical manifestations. A longitudinal study is needed to determine whether their early appearance is predictive of subsequent disease severity.

Url:

https://api.istex.fr/ark:/67375/HXZ-89VBC27C-0/fulltext.pdf

DOI: 10.1093/rheumatology/39.5.481

Links to Exploration step

ISTEX:0A72297B4B08314DD6A093A83221189C1CDE470D

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis</title>
<author><name sortKey="Vittecoq, O" sort="Vittecoq, O" uniqKey="Vittecoq O" first="O." last="Vittecoq">O. Vittecoq</name>
<affiliation><mods:affiliation>Service de Rhumatologie,</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Jouen Eades, F" sort="Jouen Eades, F" uniqKey="Jouen Eades F" first="F." last="Jouen-Beades">F. Jouen-Beades</name>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Krzanowska, K" sort="Krzanowska, K" uniqKey="Krzanowska K" first="K." last="Krzanowska">K. Krzanowska</name>
<affiliation><mods:affiliation>Service de Rhumatologie,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bichon Auvel, I" sort="Bichon Auvel, I" uniqKey="Bichon Auvel I" first="I." last="Bichon-Tauvel">I. Bichon-Tauvel</name>
<affiliation><mods:affiliation>Collège des Rhumatologues de Haute‐Normandie and</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Menard, J F" sort="Menard, J F" uniqKey="Menard J" first="J. F." last="Menard">J. F. Menard</name>
<affiliation><mods:affiliation>Unité de Biométrie‐Biostatistique, Centre Hospitalier Universitaire de Rouen, 76031 Rouen Cedex, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Daragon, A" sort="Daragon, A" uniqKey="Daragon A" first="A." last="Daragon">A. Daragon</name>
<affiliation><mods:affiliation>Service de Rhumatologie,</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Gilbert, D" sort="Gilbert, D" uniqKey="Gilbert D" first="D." last="Gilbert">D. Gilbert</name>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Tron, F" sort="Tron, F" uniqKey="Tron F" first="F." last="Tron">F. Tron</name>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Le Loe T, X" sort="Le Loe T, X" uniqKey="Le Loe T X" first="X." last="Le Loe T">X. Le Loe T</name>
<affiliation><mods:affiliation>Service de Rhumatologie,</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:0A72297B4B08314DD6A093A83221189C1CDE470D</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1093/rheumatology/39.5.481</idno>
<idno type="url">https://api.istex.fr/ark:/67375/HXZ-89VBC27C-0/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001895</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001895</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis</title>
<author><name sortKey="Vittecoq, O" sort="Vittecoq, O" uniqKey="Vittecoq O" first="O." last="Vittecoq">O. Vittecoq</name>
<affiliation><mods:affiliation>Service de Rhumatologie,</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Jouen Eades, F" sort="Jouen Eades, F" uniqKey="Jouen Eades F" first="F." last="Jouen-Beades">F. Jouen-Beades</name>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Krzanowska, K" sort="Krzanowska, K" uniqKey="Krzanowska K" first="K." last="Krzanowska">K. Krzanowska</name>
<affiliation><mods:affiliation>Service de Rhumatologie,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Bichon Auvel, I" sort="Bichon Auvel, I" uniqKey="Bichon Auvel I" first="I." last="Bichon-Tauvel">I. Bichon-Tauvel</name>
<affiliation><mods:affiliation>Collège des Rhumatologues de Haute‐Normandie and</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Menard, J F" sort="Menard, J F" uniqKey="Menard J" first="J. F." last="Menard">J. F. Menard</name>
<affiliation><mods:affiliation>Unité de Biométrie‐Biostatistique, Centre Hospitalier Universitaire de Rouen, 76031 Rouen Cedex, France</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Daragon, A" sort="Daragon, A" uniqKey="Daragon A" first="A." last="Daragon">A. Daragon</name>
<affiliation><mods:affiliation>Service de Rhumatologie,</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Gilbert, D" sort="Gilbert, D" uniqKey="Gilbert D" first="D." last="Gilbert">D. Gilbert</name>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Tron, F" sort="Tron, F" uniqKey="Tron F" first="F." last="Tron">F. Tron</name>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Le Loe T, X" sort="Le Loe T, X" uniqKey="Le Loe T X" first="X." last="Le Loe T">X. Le Loe T</name>
<affiliation><mods:affiliation>Service de Rhumatologie,</mods:affiliation>
</affiliation>
<affiliation><mods:affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Rheumatology</title>
<title level="j" type="abbrev">Rheumatology</title>
<idno type="ISSN">1462-0324</idno>
<idno type="eISSN">1462-0332</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="2000-05">2000</date>
<biblScope unit="vol">39</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="481">481</biblScope>
<biblScope unit="page" to="489">489</biblScope>
</imprint>
<idno type="ISSN">1462-0324</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1462-0324</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objectives. To evaluate the frequencies of antineutrophil cytoplasmic (ANCA), anticardiolipin (aCLA) and anti‐β2‐glycoprotein 1 antibodies (aβ2‐GP1A) in rheumatoid arthritis (RA) of limited duration in patients recruited primarily from private practitioners (80%), and to attempt to correlate the presence of these antibodies with certain clinical and/or biological criteria. Patients and methods. Patients (n = 102) with RA evolving for <5 yr (mean 2.2 yr) were recruited. A home evaluation collected clinical data [Ritchie articular index, Health Assessment Questionnaire (HAQ) index, extra‐articular manifestations] and blood for biological analyses [C‐reactive protein (CRP), rheumatoid factor, ANCA, aCLA, aβ2‐GP1A]. ANCA were detected by indirect immunofluorescence on neutrophils and their specificity was determined by enzyme‐linked immunosorbent assay (ELISA) and confirmed by immunoblotting; aCLA and aβ2‐GP1A were detected by ELISA. Results. Patients had mild RA (Ritchie = 11/78 ± 9.6; HAQ = 0.79/3 ± 0.7), probably due to the recruitment procedure. ANCA, aCLA and aβ2‐GP1A frequencies were 18.5, 7 and 0%, respectively. Titres of ANCA and aCLA were low. A perinuclear ANCA staining pattern was exclusively observed and lactoferrin was shown to be the major antigen recognized. No relationship was found between ANCA and aCLA and/or rheumatoid factor, or any clinical manifestations. ANCA were more common in RA of longer duration (cut‐off: 4 yr; P = 0.05) and aCLA were correlated with the CRP level (P = 0.05). Conclusions. In RA of recent onset, ANCA and aCLA were detected at low titres and frequencies, and were not associated with any clinical manifestations. A longitudinal study is needed to determine whether their early appearance is predictive of subsequent disease severity.</div>
</front>
</TEI>
<istex><corpusName>oup</corpusName>
<keywords><teeft><json:string>anca</json:string>
<json:string>acla</json:string>
<json:string>rheumatoid</json:string>
<json:string>elisa</json:string>
<json:string>rheumatoid arthritis</json:string>
<json:string>cytoplasmic</json:string>
<json:string>anticardiolipin</json:string>
<json:string>panca</json:string>
<json:string>anticardiolipin antibody</json:string>
<json:string>perinuclear</json:string>
<json:string>antineutrophil</json:string>
<json:string>gp1a</json:string>
<json:string>rheumatol</json:string>
<json:string>antiphospholipid</json:string>
<json:string>assay</json:string>
<json:string>positivity</json:string>
<json:string>vasculitis</json:string>
<json:string>lupus</json:string>
<json:string>recent onset</json:string>
<json:string>immunol</json:string>
<json:string>immunoblotting</json:string>
<json:string>antineutrophil cytoplasmic antibody</json:string>
<json:string>antibody population</json:string>
<json:string>arthritis</json:string>
<json:string>rheum</json:string>
<json:string>goat antihuman</json:string>
<json:string>alkaline phosphatase</json:string>
<json:string>cytospin preparation</json:string>
<json:string>staining pattern</json:string>
<json:string>antineutrophil cytoplasmic</json:string>
<json:string>vascular lesion</json:string>
<json:string>rheumatoid factor</json:string>
<json:string>health assessment questionnaire</json:string>
<json:string>systemic lupus erythematosus</json:string>
<json:string>anca frequency</json:string>
<json:string>positive correlation</json:string>
<json:string>prospective study</json:string>
<json:string>antibody</json:string>
<json:string>rheumatoid vasculitis</json:string>
<json:string>leucocyte protein</json:string>
<json:string>uncoated well</json:string>
<json:string>biological analysis protein</json:string>
<json:string>immunosorbent assay</json:string>
<json:string>antilactoferrin antibody</json:string>
<json:string>individual patient</json:string>
<json:string>statistical analysis</json:string>
<json:string>qualitative variable</json:string>
<json:string>rheumatoid nodule</json:string>
<json:string>prognostic value</json:string>
<json:string>major antigen</json:string>
<json:string>gp1a frequency</json:string>
<json:string>antinuclear antibody</json:string>
<json:string>acla activity</json:string>
<json:string>clinical datum</json:string>
<json:string>antibody titre</json:string>
<json:string>clinical manifestation</json:string>
<json:string>immunological marker</json:string>
<json:string>long duration</json:string>
<json:string>private recruitment</json:string>
<json:string>high rate</json:string>
<json:string>clinical correlation</json:string>
<json:string>previous study</json:string>
<json:string>target antigen</json:string>
<json:string>such antibody</json:string>
<json:string>severe vasculitis</json:string>
<json:string>thrombotic event</json:string>
<json:string>antiphospholipid syndrome</json:string>
<json:string>monoclonal antibody</json:string>
<json:string>healthy individual</json:string>
<json:string>ritchie index</json:string>
<json:string>semin arthritis rheum</json:string>
<json:string>private practitioner</json:string>
<json:string>cytoplasmic antibody</json:string>
<json:string>antiphospholipid antibody</json:string>
<json:string>rheumatic disease</json:string>
<json:string>connective tissue disease</json:string>
<json:string>latex test</json:string>
</teeft>
</keywords>
<author><json:item><name>O. Vittecoq</name>
<affiliations><json:string>Service de Rhumatologie,</json:string>
<json:string>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</json:string>
</affiliations>
</json:item>
<json:item><name>F. Jouen‐Beades</name>
<affiliations><json:string>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</json:string>
</affiliations>
</json:item>
<json:item><name>K. Krzanowska</name>
<affiliations><json:string>Service de Rhumatologie,</json:string>
</affiliations>
</json:item>
<json:item><name>I. Bichon‐Tauvel</name>
<affiliations><json:string>Collège des Rhumatologues de Haute‐Normandie and</json:string>
</affiliations>
</json:item>
<json:item><name>J. F. Menard</name>
<affiliations><json:string>Unité de Biométrie‐Biostatistique, Centre Hospitalier Universitaire de Rouen, 76031 Rouen Cedex, France</json:string>
</affiliations>
</json:item>
<json:item><name>A. Daragon</name>
<affiliations><json:string>Service de Rhumatologie,</json:string>
<json:string>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</json:string>
</affiliations>
</json:item>
<json:item><name>D. Gilbert</name>
<affiliations><json:string>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</json:string>
</affiliations>
</json:item>
<json:item><name>F. Tron</name>
<affiliations><json:string>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</json:string>
</affiliations>
</json:item>
<json:item><name>X. Le Loët</name>
<affiliations><json:string>Service de Rhumatologie,</json:string>
<json:string>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</json:string>
</affiliations>
</json:item>
</author>
<subject><json:item><lang><json:string>eng</json:string>
</lang>
<value>Rheumatoid arthritis</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>ANCA</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Anticardiolipin antibodies</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Anti‐β2‐glycoprotein 1 antibodies</value>
</json:item>
<json:item><lang><json:string>eng</json:string>
</lang>
<value>Antilactoferrin antibodies.</value>
</json:item>
</subject>
<arkIstex>ark:/67375/HXZ-89VBC27C-0</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>other</json:string>
</originalGenre>
<abstract>Objectives. To evaluate the frequencies of antineutrophil cytoplasmic (ANCA), anticardiolipin (aCLA) and anti‐β2‐glycoprotein 1 antibodies (aβ2‐GP1A) in rheumatoid arthritis (RA) of limited duration in patients recruited primarily from private practitioners (80%), and to attempt to correlate the presence of these antibodies with certain clinical and/or biological criteria. Patients and methods. Patients (n = 102) with RA evolving for >5 yr (mean 2.2 yr) were recruited. A home evaluation collected clinical data [Ritchie articular index, Health Assessment Questionnaire (HAQ) index, extra‐articular manifestations] and blood for biological analyses [C‐reactive protein (CRP), rheumatoid factor, ANCA, aCLA, aβ2‐GP1A]. ANCA were detected by indirect immunofluorescence on neutrophils and their specificity was determined by enzyme‐linked immunosorbent assay (ELISA) and confirmed by immunoblotting; aCLA and aβ2‐GP1A were detected by ELISA. Results. Patients had mild RA (Ritchie = 11/78 ± 9.6; HAQ = 0.79/3 ± 0.7), probably due to the recruitment procedure. ANCA, aCLA and aβ2‐GP1A frequencies were 18.5, 7 and 0%, respectively. Titres of ANCA and aCLA were low. A perinuclear ANCA staining pattern was exclusively observed and lactoferrin was shown to be the major antigen recognized. No relationship was found between ANCA and aCLA and/or rheumatoid factor, or any clinical manifestations. ANCA were more common in RA of longer duration (cut‐off: 4 yr; P = 0.05) and aCLA were correlated with the CRP level (P = 0.05). Conclusions. In RA of recent onset, ANCA and aCLA were detected at low titres and frequencies, and were not associated with any clinical manifestations. A longitudinal study is needed to determine whether their early appearance is predictive of subsequent disease severity.</abstract>
<qualityIndicators><score>8</score>
<pdfWordCount>5175</pdfWordCount>
<pdfCharCount>34217</pdfCharCount>
<pdfVersion>1.3</pdfVersion>
<pdfPageCount>9</pdfPageCount>
<pdfPageSize>595 x 842 pts (A4)</pdfPageSize>
<pdfWordsPerPage>575</pdfWordsPerPage>
<pdfText>true</pdfText>
<refBibsNative>true</refBibsNative>
<abstractWordCount>262</abstractWordCount>
<abstractCharCount>1798</abstractCharCount>
<keywordCount>5</keywordCount>
</qualityIndicators>
<title>Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis</title>
<pmid><json:string>10852977</json:string>
</pmid>
<pii><json:string>1460-2172</json:string>
</pii>
<genre><json:string>other</json:string>
</genre>
<host><title>Rheumatology</title>
<language><json:string>unknown</json:string>
</language>
<issn><json:string>1462-0324</json:string>
</issn>
<eissn><json:string>1462-0332</json:string>
</eissn>
<publisherId><json:string>brheum</json:string>
</publisherId>
<volume>39</volume>
<issue>5</issue>
<pages><first>481</first>
<last>489</last>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<namedEntities><unitex><date><json:string>2000</json:string>
</date>
<geogName></geogName>
<orgName><json:string>Hospital Hospital Hospital Hospital Hospital Hospital Private Duration of RA</json:string>
<json:string>Hospital Hospital Hospital Hospital</json:string>
<json:string>Hospital Hospital Hospital</json:string>
<json:string>Department of Rheumatology of the Rouen University Hospital</json:string>
<json:string>Caltag Laboratories, San Francisco</json:string>
<json:string>ACR</json:string>
<json:string>Hospital Hospital</json:string>
<json:string>Flow Laboratories</json:string>
<json:string>Calbiochem</json:string>
<json:string>Biomedical Diagnostics, Marne</json:string>
<json:string>International Congress</json:string>
<json:string>American College of Rheumatology</json:string>
<json:string>Societe Francaise</json:string>
</orgName>
<orgName_funder><json:string>Societe Francaise</json:string>
</orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>J. F. Menard</json:string>
<json:string>D. Gilbert</json:string>
<json:string>K. Krzanowska</json:string>
<json:string>Janet Jacobson</json:string>
<json:string>X. Le Loet</json:string>
<json:string>F. Tron</json:string>
<json:string>ELISA Ethanol</json:string>
<json:string>de Haute-Normandie</json:string>
<json:string>F. Jouen-Beades</json:string>
<json:string>O. Vittecoq</json:string>
<json:string>Reference</json:string>
<json:string>Patient</json:string>
<json:string>A. Daragon</json:string>
<json:string>Maquin</json:string>
<json:string>de Haute</json:string>
<json:string>I. Bichon-Tauvel</json:string>
<json:string>La Jolla</json:string>
<json:string>Jackson Immunoresearch</json:string>
</persName>
<placeName><json:string>San Diego</json:string>
<json:string>UK</json:string>
<json:string>USA</json:string>
<json:string>Strasbourg</json:string>
<json:string>Puri</json:string>
<json:string>CA</json:string>
<json:string>France</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>[16, 17, 23, 24]</json:string>
<json:string>[34]</json:string>
<json:string>[15, 29, 30, 37]</json:string>
<json:string>[15, 17, 18, 36 ]</json:string>
<json:string>Wolf et al. [30]</json:string>
<json:string>Merkel et al. [31]</json:string>
<json:string>[44]</json:string>
<json:string>[8]</json:string>
<json:string>Braun et al. [22]</json:string>
<json:string>[17, 24, 31]</json:string>
<json:string>Kaburaki et al. [41]</json:string>
<json:string>[1]</json:string>
<json:string>Helsloot et al. [20]</json:string>
<json:string>[10]</json:string>
<json:string>[5, 6 ]</json:string>
<json:string>[21, 22, 25, 33]</json:string>
<json:string>O. Vittecoq et al.</json:string>
<json:string>[27]</json:string>
<json:string>Keane et al. [27]</json:string>
<json:string>[17, 21, 25]</json:string>
<json:string>Coremans et al. [16 ]</json:string>
<json:string>[16 ]</json:string>
<json:string>Mustila et al. [25]</json:string>
<json:string>Mulder et al. [17]</json:string>
<json:string>[21, 32]</json:string>
<json:string>Nassberger et al. [18]</json:string>
<json:string>[16, 19, 22, 33]</json:string>
<json:string>de Bandt et al. [24]</json:string>
<json:string>Cambridge et al. [19]</json:string>
<json:string>Seriolo et al. [29]</json:string>
<json:string>Afeltra et al. [23]</json:string>
<json:string>[41]</json:string>
<json:string>Nassberger et al. [15]</json:string>
<json:string>[7]</json:string>
<json:string>[25]</json:string>
<json:string>Bosch et al. [21]</json:string>
<json:string>Fort et al. [26 ]</json:string>
<json:string>[42, 43]</json:string>
<json:string>[9]</json:string>
<json:string>[40]</json:string>
<json:string>[26, 29]</json:string>
<json:string>[2]</json:string>
<json:string>[24]</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/HXZ-89VBC27C-0</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - rheumatology</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - arthritis & rheumatology</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Pharmacology (medical)</json:string>
<json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - Rheumatology</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
<json:string>4 - pathologie osteoarticulaire</json:string>
</inist>
</categories>
<publicationDate>2000</publicationDate>
<copyrightDate>2000</copyrightDate>
<doi><json:string>10.1093/rheumatology/39.5.481</json:string>
</doi>
<id>0A72297B4B08314DD6A093A83221189C1CDE470D</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-89VBC27C-0/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-89VBC27C-0/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/HXZ-89VBC27C-0/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>Oxford University Press</publisher>
<availability><licence>© British Society for Rheumatology</licence>
</availability>
<date when="2000-05">2000</date>
<date type="Copyright" when="2000">2000</date>
</publicationStmt>
<notesStmt><note type="content-type" source="other" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note>
<note type="publication-type" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="other"><analytic><title level="a" type="main" xml:lang="en">Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis</title>
<author xml:id="author-0000"><persName><surname>Vittecoq</surname>
<forename type="first">O.</forename>
</persName>
<affiliation><orgName type="laboratory">Service de Rhumatologie</orgName>
</affiliation>
<affiliation><orgName type="institution">INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides</orgName>
</affiliation>
</author>
<author xml:id="author-0001"><persName><surname>Jouen‐Beades</surname>
<forename type="first">F.</forename>
</persName>
<affiliation><orgName type="institution">INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides</orgName>
</affiliation>
</author>
<author xml:id="author-0002"><persName><surname>Krzanowska</surname>
<forename type="first">K.</forename>
</persName>
<affiliation><orgName type="laboratory">Service de Rhumatologie</orgName>
</affiliation>
</author>
<author xml:id="author-0003"><persName><surname>Bichon‐Tauvel</surname>
<forename type="first">I.</forename>
</persName>
<affiliation><orgName type="">Collège des Rhumatologues de Haute‐Normandie and</orgName>
</affiliation>
</author>
<author xml:id="author-0004"><persName><surname>Menard</surname>
<forename type="first">J. F.</forename>
</persName>
<affiliation><orgName type="laboratory">Unité de Biométrie‐Biostatistique</orgName>
<address><addrLine>Centre Hospitalier Universitaire de Rouen, 76031 Rouen Cedex, France</addrLine>
<country key="FR" xml:lang="en">FRANCE</country>
</address>
</affiliation>
</author>
<author xml:id="author-0005"><persName><surname>Daragon</surname>
<forename type="first">A.</forename>
</persName>
<affiliation><orgName type="laboratory">Service de Rhumatologie</orgName>
</affiliation>
<affiliation><orgName type="institution">INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides</orgName>
</affiliation>
</author>
<author xml:id="author-0006"><persName><surname>Gilbert</surname>
<forename type="first">D.</forename>
</persName>
<affiliation><orgName type="institution">INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides</orgName>
</affiliation>
</author>
<author xml:id="author-0007"><persName><surname>Tron</surname>
<forename type="first">F.</forename>
</persName>
<affiliation><orgName type="institution">INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides</orgName>
</affiliation>
</author>
<author xml:id="author-0008"><persName><surname>Le Loët</surname>
<forename type="first">X.</forename>
</persName>
<affiliation><orgName type="laboratory">Service de Rhumatologie</orgName>
</affiliation>
<affiliation><orgName type="institution">INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides</orgName>
</affiliation>
</author>
<idno type="istex">0A72297B4B08314DD6A093A83221189C1CDE470D</idno>
<idno type="ark">ark:/67375/HXZ-89VBC27C-0</idno>
<idno type="other">0390481</idno>
<idno type="DOI">10.1093/rheumatology/39.5.481</idno>
<idno type="PII">1460-2172</idno>
</analytic>
<monogr><title level="j" type="main">Rheumatology</title>
<title level="j" type="abbrev">Rheumatology</title>
<idno type="hwp">rheumatology</idno>
<idno type="nlm-ta">Rheumatology (Oxford)</idno>
<idno type="publisher-id">brheum</idno>
<idno type="pISSN">1462-0324</idno>
<idno type="eISSN">1462-0332</idno>
<imprint><publisher>Oxford University Press</publisher>
<date when="2000-05">2000</date>
<biblScope unit="vol">39</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="481">481</biblScope>
<biblScope unit="page" to="489">489</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef>
<appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-09"><label>pub2TEI-ISTEX</label>
<desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
                        <ref target="http://www.tei-c.org/">We use TEI</ref>
</desc>
</application>
</appInfo>
</encodingDesc>
<profileDesc><abstract xml:lang="en"><p><hi rend="italic">Objectives</hi>
. To evaluate the frequencies of antineutrophil cytoplasmic (ANCA), anticardiolipin (aCLA) and anti‐<hi rend="italic">β</hi>
<hi rend="subscript">2</hi>
‐glycoprotein 1 antibodies (a<hi rend="italic">β</hi>
<hi rend="subscript">2</hi>
‐GP1A) in rheumatoid arthritis (RA) of limited duration in patients recruited primarily from private practitioners (80%), and to attempt to correlate the presence of these antibodies with certain clinical and/or biological criteria.</p>
<p><hi rend="italic">Patients and methods</hi>
. Patients (<hi rend="italic">n</hi>
 = 102) with RA evolving for <5 yr (mean 2.2 yr) were recruited. A home evaluation collected clinical data [Ritchie articular index, Health Assessment Questionnaire (HAQ) index, extra‐articular manifestations] and blood for biological analyses [C‐reactive protein (CRP), rheumatoid factor, ANCA, aCLA, a<hi rend="italic">β</hi>
<hi rend="subscript">2</hi>
‐GP1A]. ANCA were detected by indirect immunofluorescence on neutrophils and their specificity was determined by enzyme‐linked immunosorbent assay (ELISA) and confirmed by immunoblotting; aCLA and a<hi rend="italic">β</hi>
<hi rend="subscript">2</hi>
‐GP1A were detected by ELISA.</p>
<p><hi rend="italic">Results</hi>
. Patients had mild RA (Ritchie = 11/78 ± 9.6; HAQ = 0.79/3 ± 0.7), probably due to the recruitment procedure. ANCA, aCLA and a<hi rend="italic">β</hi>
<hi rend="subscript">2</hi>
‐GP1A frequencies were 18.5, 7 and 0%, respectively. Titres of ANCA and aCLA were low. A perinuclear ANCA staining pattern was exclusively observed and lactoferrin was shown to be the major antigen recognized. No relationship was found between ANCA and aCLA and/or rheumatoid factor, or any clinical manifestations. ANCA were more common in RA of longer duration (cut‐off: 4 yr; <hi rend="italic">P</hi>
 = 0.05) and aCLA were correlated with the CRP level (<hi rend="italic">P</hi>
 = 0.05).</p>
<p><hi rend="italic">Conclusions</hi>
. In RA of recent onset, ANCA and aCLA were detected at low titres and frequencies, and were not associated with any clinical manifestations. A longitudinal study is needed to determine whether their early appearance is predictive of subsequent disease severity.</p>
</abstract>
<textClass ana="subject"><keywords scheme="heading"><term>Original Papers</term>
</keywords>
</textClass>
<textClass ana="keyword"><keywords scheme="KWD" xml:lang="en"><term>Rheumatoid arthritis</term>
<term>ANCA</term>
<term>Anticardiolipin antibodies</term>
<term>Anti‐<hi rend="italic">β</hi>
<hi rend="subscript">2</hi>
‐glycoprotein 1 antibodies</term>
<term>Antilactoferrin antibodies.</term>
</keywords>
</textClass>
<langUsage><language ident="en"></language>
</langUsage>
</profileDesc>
<revisionDesc><change when="2019-12-09" who="#istex" xml:id="pub2tei">formatting</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-89VBC27C-0/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus oup, element #text not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="US-ASCII"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType>
<istex:document><article xml:lang="en" article-type="other"><front><journal-meta><journal-id journal-id-type="hwp">rheumatology</journal-id>
<journal-id journal-id-type="nlm-ta">Rheumatology (Oxford)</journal-id>

<journal-id journal-id-type="publisher-id">brheum</journal-id>
<journal-title>Rheumatology</journal-title>
<abbrev-journal-title abbrev-type="publisher">Rheumatology</abbrev-journal-title>
<issn pub-type="ppub">1462-0324</issn>
<issn pub-type="epub">1462-0332</issn>
<publisher><publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="other">0390481</article-id>

<article-id pub-id-type="doi">10.1093/rheumatology/39.5.481</article-id>
<article-id pub-id-type="pii">1460-2172</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group><article-title>Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis</article-title>
</title-group>
<contrib-group>

      <contrib contrib-type="author"><name><surname>Vittecoq</surname>
<given-names>O.</given-names>
</name>

        

        

      

      <xref rid="AFF1">

        <sup>1</sup>

      </xref>

      <xref rid="AFF2">

        <sup>2</sup>

      </xref>

      <xref rid="FN1"></xref>

      </contrib>
<contrib contrib-type="author"><name><surname>Jouen‐Beades</surname>
<given-names>F.</given-names>
</name>

        

        

      

      <xref rid="AFF2">

        <sup>2</sup>

      </xref>

      </contrib>
<contrib contrib-type="author"><name><surname>Krzanowska</surname>
<given-names>K.</given-names>
</name>

        

        

      

      <xref rid="AFF1">

        <sup>1</sup>

      </xref>

      </contrib>
<contrib contrib-type="author"><name><surname>Bichon‐Tauvel</surname>
<given-names>I.</given-names>
</name>

        

        

      

      <xref rid="AFF3">

        <sup>3</sup>

      </xref>

      </contrib>
<contrib contrib-type="author"><name><surname>Menard</surname>
<given-names>J. F.</given-names>
</name>

        

        

      

      <xref rid="AFF4">

        <sup>4</sup>

      </xref>

      </contrib>
<contrib contrib-type="author"><name><surname>Daragon</surname>
<given-names>A.</given-names>
</name>

        

        

      

      <xref rid="AFF1">

        <sup>1</sup>

      </xref>

      <xref rid="AFF2">

        <sup>2</sup>

      </xref>

      </contrib>
<contrib contrib-type="author"><name><surname>Gilbert</surname>
<given-names>D.</given-names>
</name>

        

        

      

      <xref rid="AFF2">

        <sup>2</sup>

      </xref>

      </contrib>
<contrib contrib-type="author"><name><surname>Tron</surname>
<given-names>F.</given-names>
</name>

        

        

      

      <xref rid="AFF2">

        <sup>2</sup>

      </xref>

      </contrib>
<contrib contrib-type="author"><name><surname>Le Loët</surname>
<given-names>X.</given-names>
</name>

        

        

      

      <xref rid="AFF1">

        <sup>1</sup>

      </xref>

      <xref rid="AFF2">

        <sup>2</sup>

      </xref>

      

      

      

      

    </contrib>
<aff id="AFF1"><label>1</label>
Service de Rhumatologie,</aff>
<aff id="AFF2"><label>2</label>
INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</aff>
<aff id="AFF3"><label>3</label>
Collège des Rhumatologues de Haute‐Normandie and</aff>
<aff id="AFF4"><label>4</label>
Unité de Biométrie‐Biostatistique, Centre Hospitalier Universitaire de Rouen, 76031 Rouen Cedex, France</aff>
</contrib-group>
<pub-date pub-type="ppub"><month>5</month>
<year>2000</year>
</pub-date>
<volume>39</volume>
<issue>5</issue>
<fpage>481</fpage>
<lpage>489</lpage>
<history><date date-type="received"><day>15</day>
<month>10</month>
<year>1998</year>
</date>
<date date-type="rev-recd"><day>23</day>
<month>11</month>
<year>1999</year>
</date>
</history>
<permissions><copyright-statement>© British Society for Rheumatology</copyright-statement>
<copyright-year>2000</copyright-year>
</permissions>
<abstract xml:lang="en">

      <p><italic>Objectives</italic>
. To evaluate the frequencies of antineutrophil cytoplasmic (ANCA), anticardiolipin (aCLA) and anti‐<italic>β</italic>
<sub>2</sub>
‐glycoprotein 1 antibodies (a<italic>β</italic>
<sub>2</sub>
‐GP1A) in rheumatoid arthritis (RA) of limited duration in patients recruited primarily from private practitioners (80%), and to attempt to correlate the presence of these antibodies with certain clinical and/or biological criteria.</p>

      <p><italic>Patients and methods</italic>
. Patients (<italic>n</italic>
 = 102) with RA evolving for <5 yr (mean 2.2 yr) were recruited. A home evaluation collected clinical data [Ritchie articular index, Health Assessment Questionnaire (HAQ) index, extra‐articular manifestations] and blood for biological analyses [C‐reactive protein (CRP), rheumatoid factor, ANCA, aCLA, a<italic>β</italic>
<sub>2</sub>
‐GP1A]. ANCA were detected by indirect immunofluorescence on neutrophils and their specificity was determined by enzyme‐linked immunosorbent assay (ELISA) and confirmed by immunoblotting; aCLA and a<italic>β</italic>
<sub>2</sub>
‐GP1A were detected by ELISA.</p>

      <p><italic>Results</italic>
. Patients had mild RA (Ritchie = 11/78 ± 9.6; HAQ = 0.79/3 ± 0.7), probably due to the recruitment procedure. ANCA, aCLA and a<italic>β</italic>
<sub>2</sub>
‐GP1A frequencies were 18.5, 7 and 0%, respectively. Titres of ANCA and aCLA were low. A perinuclear ANCA staining pattern was exclusively observed and lactoferrin was shown to be the major antigen recognized. No relationship was found between ANCA and aCLA and/or rheumatoid factor, or any clinical manifestations. ANCA were more common in RA of longer duration (cut‐off: 4 yr; <italic>P</italic>
 = 0.05) and aCLA were correlated with the CRP level (<italic>P</italic>
 = 0.05).</p>

      <p><italic>Conclusions</italic>
. In RA of recent onset, ANCA and aCLA were detected at low titres and frequencies, and were not associated with any clinical manifestations. A longitudinal study is needed to determine whether their early appearance is predictive of subsequent disease severity.</p>

    </abstract>
<kwd-group kwd-group-type="KWD" xml:lang="en">

      <kwd>Rheumatoid arthritis</kwd>

      <kwd>ANCA</kwd>

      <kwd>Anticardiolipin antibodies</kwd>

      <kwd>Anti‐<italic>β</italic>
<sub>2</sub>
‐glycoprotein 1 antibodies</kwd>

      <kwd>Antilactoferrin antibodies.</kwd>

    </kwd-group>
<custom-meta-wrap><custom-meta><meta-name>hwp-legacy-fpage</meta-name>
<meta-value>481</meta-value>
</custom-meta>
<custom-meta><meta-name>hwp-legacy-dochead</meta-name>
<meta-value>Original Papers</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>

  

  

  

    

    

    

    

    

    

  

  

  

    

    

  

</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis</title>
</titleInfo>
<titleInfo type="alternative" lang="en" contentType="CDATA"><title>Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis</title>
</titleInfo>
<name type="personal"><namePart type="given">O.</namePart>
<namePart type="family">Vittecoq</namePart>
<affiliation>Service de Rhumatologie,</affiliation>
<affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">F.</namePart>
<namePart type="family">Jouen‐Beades</namePart>
<affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">K.</namePart>
<namePart type="family">Krzanowska</namePart>
<affiliation>Service de Rhumatologie,</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">I.</namePart>
<namePart type="family">Bichon‐Tauvel</namePart>
<affiliation>Collège des Rhumatologues de Haute‐Normandie and</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">J. F.</namePart>
<namePart type="family">Menard</namePart>
<affiliation>Unité de Biométrie‐Biostatistique, Centre Hospitalier Universitaire de Rouen, 76031 Rouen Cedex, France</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A.</namePart>
<namePart type="family">Daragon</namePart>
<affiliation>Service de Rhumatologie,</affiliation>
<affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">D.</namePart>
<namePart type="family">Gilbert</namePart>
<affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">F.</namePart>
<namePart type="family">Tron</namePart>
<affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">X.</namePart>
<namePart type="family">Le Loët</namePart>
<affiliation>Service de Rhumatologie,</affiliation>
<affiliation>INSERM U 519 et Institut Fédératif de Recherche Multidisciplinaire sur les Peptides,</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="other" displayLabel="other" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre>
<originInfo><publisher>Oxford University Press</publisher>
<dateIssued encoding="w3cdtf">2000-05</dateIssued>
<copyrightDate encoding="w3cdtf">2000</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<abstract lang="en">Objectives. To evaluate the frequencies of antineutrophil cytoplasmic (ANCA), anticardiolipin (aCLA) and anti‐β2‐glycoprotein 1 antibodies (aβ2‐GP1A) in rheumatoid arthritis (RA) of limited duration in patients recruited primarily from private practitioners (80%), and to attempt to correlate the presence of these antibodies with certain clinical and/or biological criteria. Patients and methods. Patients (n = 102) with RA evolving for <5 yr (mean 2.2 yr) were recruited. A home evaluation collected clinical data [Ritchie articular index, Health Assessment Questionnaire (HAQ) index, extra‐articular manifestations] and blood for biological analyses [C‐reactive protein (CRP), rheumatoid factor, ANCA, aCLA, aβ2‐GP1A]. ANCA were detected by indirect immunofluorescence on neutrophils and their specificity was determined by enzyme‐linked immunosorbent assay (ELISA) and confirmed by immunoblotting; aCLA and aβ2‐GP1A were detected by ELISA. Results. Patients had mild RA (Ritchie = 11/78 ± 9.6; HAQ = 0.79/3 ± 0.7), probably due to the recruitment procedure. ANCA, aCLA and aβ2‐GP1A frequencies were 18.5, 7 and 0%, respectively. Titres of ANCA and aCLA were low. A perinuclear ANCA staining pattern was exclusively observed and lactoferrin was shown to be the major antigen recognized. No relationship was found between ANCA and aCLA and/or rheumatoid factor, or any clinical manifestations. ANCA were more common in RA of longer duration (cut‐off: 4 yr; P = 0.05) and aCLA were correlated with the CRP level (P = 0.05). Conclusions. In RA of recent onset, ANCA and aCLA were detected at low titres and frequencies, and were not associated with any clinical manifestations. A longitudinal study is needed to determine whether their early appearance is predictive of subsequent disease severity.</abstract>
<subject lang="en"><genre>KWD</genre>
<topic>Rheumatoid arthritis</topic>
<topic>ANCA</topic>
<topic>Anticardiolipin antibodies</topic>
<topic>Anti‐β2‐glycoprotein 1 antibodies</topic>
<topic>Antilactoferrin antibodies.</topic>
</subject>
<relatedItem type="host"><titleInfo><title>Rheumatology</title>
</titleInfo>
<titleInfo type="abbreviated"><title>Rheumatology</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<identifier type="ISSN">1462-0324</identifier>
<identifier type="eISSN">1462-0332</identifier>
<identifier type="PublisherID">brheum</identifier>
<identifier type="PublisherID-hwp">rheumatology</identifier>
<identifier type="PublisherID-nlm-ta">Rheumatology (Oxford)</identifier>
<part><date>2000</date>
<detail type="volume"><caption>vol.</caption>
<number>39</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>5</number>
</detail>
<extent unit="pages"><start>481</start>
<end>489</end>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R1"><titleInfo><title>Rheum Dis Clin North Am</title>
</titleInfo>
<note>Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am1990;16:513–37.</note>
<part><date>1990</date>
<detail type="volume"><caption>vol.</caption>
<number>16</number>
</detail>
<extent unit="pages"><start>513</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R2"><titleInfo><title>Ann Rheum Dis</title>
</titleInfo>
<note>Van Zeben D, Hazes JMW, Zwinderman AH, Cats A, van der Voort EAM, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow‐up study. Ann Rheum Dis1992;51:1029–35.</note>
<part><date>1992</date>
<detail type="volume"><caption>vol.</caption>
<number>51</number>
</detail>
<extent unit="pages"><start>1029</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R3"><titleInfo><title>Semin Arthritis Rheum</title>
</titleInfo>
<note>Aho K, Palusuo T, Kurki P. Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum1994;23:379–87.</note>
<part><date>1994</date>
<detail type="volume"><caption>vol.</caption>
<number>23</number>
</detail>
<extent unit="pages"><start>379</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R4"><titleInfo><title>Rev Rhum [Engl. Ed]</title>
</titleInfo>
<note>Vittecoq O, Jouen‐Beades F, Delpech A, Gilbert D, Le Loët X, Tron F. Autoantibodies in rheumatoid arthritis. Rev Rhum [Engl. Ed]1995;62:195S–200S.</note>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>62</number>
</detail>
<extent unit="pages"><start>195S</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R5"><titleInfo><title>Br J Rheumatol</title>
</titleInfo>
<note>Combe B, Eliaou JF, Daurès JP, Meyer O, Clot J, Sany J. Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol1995;34:529–34.</note>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>34</number>
</detail>
<extent unit="pages"><start>529</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R6"><titleInfo><title>Arthritis Rheum</title>
</titleInfo>
<note>Wagner U, Kaltenhauser S, Sauer H et al. HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum1997;40:341–51.</note>
<part><date>1997</date>
<detail type="volume"><caption>vol.</caption>
<number>40</number>
</detail>
<extent unit="pages"><start>341</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R7"><titleInfo><title>Rev Rhum Mal Osteoartic</title>
</titleInfo>
<note>Wattiaux MJ, Kahn MF, Bourgeois P, Vinceneux Ph, Grossin M, Kaplan G. Analyse anatomique et nosologique de 100 cas d'angéites diffuses vues en Rhumatologie. Rev Rhum Mal Osteoartic1985;52:599–603.</note>
<part><date>1985</date>
<detail type="volume"><caption>vol.</caption>
<number>52</number>
</detail>
<extent unit="pages"><start>599</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R8"><titleInfo><title>Semin Arthritis Rheum</title>
</titleInfo>
<note>Schultz DR, Tozman EC. Anti‐neutrophil cytoplasmic antibodies: major autoantigens, pathophysiology, and disease associations. Semin Arthritis Rheum1995;25:143–59.</note>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>25</number>
</detail>
<extent unit="pages"><start>143</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R9"><titleInfo><title>Lupus</title>
</titleInfo>
<note>Lockshin MD. Pathogenesis of the antiphospholipid antibody syndrome. Lupus1996;5:404–8.</note>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>5</number>
</detail>
<extent unit="pages"><start>404</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R10"><titleInfo><title>Proc Natl Acad Sci USA</title>
</titleInfo>
<note>McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid‐binding inhibitor of coagulation β2‐glycoprotein 1 (apolipoprotein H). Proc Natl Acad Sci USA1990;87:4120–4.</note>
<part><date>1990</date>
<detail type="volume"><caption>vol.</caption>
<number>87</number>
</detail>
<extent unit="pages"><start>4120</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R11"><titleInfo><title>Arthritis Rheum</title>
</titleInfo>
<note>Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1998;31:315–24.</note>
<part><date>1998</date>
<detail type="volume"><caption>vol.</caption>
<number>31</number>
</detail>
<extent unit="pages"><start>315</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R12"><titleInfo><title>Rev Rhum</title>
</titleInfo>
<note>Guillemin F, Briançon S, Pourel J. Mesure de la capacité fonctionnelle dans la polyarthrite rhumatoide: adaptation française du Health Assessment Questionnaire. Rev Rhum1991;58:459–65.</note>
<part><date>1991</date>
<detail type="volume"><caption>vol.</caption>
<number>58</number>
</detail>
<extent unit="pages"><start>459</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R13"><titleInfo><title>APMIS</title>
</titleInfo>
<note>Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS1989;97(Suppl. 6):12–3.</note>
<part><date>1989</date>
<detail type="volume"><caption>vol.</caption>
<number>97(Suppl. 6)</number>
</detail>
<extent unit="pages"><start>12</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R14"><titleInfo><title>Am J Clin Path</title>
</titleInfo>
<note>Harris EN. Special report. The second international anti‐cardiolipin standardization workshop/the Kingston anti‐phospholipid antibody study (KAPS) group. Am J Clin Path1990;94:476–84.</note>
<part><date>1990</date>
<detail type="volume"><caption>vol.</caption>
<number>94</number>
</detail>
<extent unit="pages"><start>476</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R15"><titleInfo><title>Scand J Rheumatol</title>
</titleInfo>
<note>Nässberger L, Sjöholm AG, Sturfelt G. Absence of circulating antineutrophil cytoplasmic antibodies (ANCA) in severe vasculitis associated with rheumatoid arthritis. Scand J Rheumatol1990;19:189–92.</note>
<part><date>1990</date>
<detail type="volume"><caption>vol.</caption>
<number>19</number>
</detail>
<extent unit="pages"><start>189</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R16"><titleInfo><title>Arthritis Rheum</title>
</titleInfo>
<note>Coremans IEM, Hagen EC, Daha MR et al. Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum1992;35:1466–75.</note>
<part><date>1992</date>
<detail type="volume"><caption>vol.</caption>
<number>35</number>
</detail>
<extent unit="pages"><start>1466</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R17"><titleInfo><title>Arthritis Rheum</title>
</titleInfo>
<note>Mulder AHL, Horst G, van Leeuwen MA, Limburg PC, Kallenberg CGM. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations. Arthritis Rheum1993;36:1054–60.</note>
<part><date>1993</date>
<detail type="volume"><caption>vol.</caption>
<number>36</number>
</detail>
<extent unit="pages"><start>1054</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R18"><titleInfo><title>Scand J Rheumatol</title>
</titleInfo>
<note>Nässberger L, Hultquist R, Sturfelt G. Occurrence of anti‐lactoferrin antibodies in patients with systemic lupus erythematosus, hydralazine‐induced lupus, and rheumatoid arthritis. Scand J Rheumatol1994;23:206–10.</note>
<part><date>1994</date>
<detail type="volume"><caption>vol.</caption>
<number>23</number>
</detail>
<extent unit="pages"><start>206</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R19"><titleInfo><title>Ann Rheum Dis</title>
</titleInfo>
<note>Cambridge G, Williams M, Leaker B, Corbett M, Smith CR. Anti‐myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass. Ann Rheum Dis1994;53:24–9.</note>
<part><date>1994</date>
<detail type="volume"><caption>vol.</caption>
<number>53</number>
</detail>
<extent unit="pages"><start>24</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R20"><titleInfo><title>Br J Rheumatol</title>
</titleInfo>
<note>Helsloot J, Virgo S, McGuigan L, Sturgess A. Antineutrophil cytoplasmic antibodies in inflammatory arthritis—Potential for misdiagnosis? Br J Rheumatol1995;34:820–4.</note>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>34</number>
</detail>
<extent unit="pages"><start>820</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R21"><titleInfo><title>J Rheumatol</title>
</titleInfo>
<note>Bosch X, Llena J, Collado A et al. Occurrence of antineutrophil cytoplasmic and antineutrophil (peri)nuclear antibodies in rheumatoid arthritis. J Rheumatol1995;22:2038–45.</note>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>22</number>
</detail>
<extent unit="pages"><start>2038</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R22"><titleInfo><title>J Rheumatol</title>
</titleInfo>
<note>Braun MG, Csernok E, Schmitt WH, Gross WL. Incidence, target antigens, and clinical implications of antineutrophil cytoplasmic antibodies in rheumatoid arthritis. J Rheumatol1996;23:826–30.</note>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>23</number>
</detail>
<extent unit="pages"><start>826</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R23"><titleInfo><title>J Rheumatol</title>
</titleInfo>
<note>Afeltra A, Sebastiani GD, Galeazzi M et al. Antineutrophil cytoplasmic antibodies in synovial fluid and in serum of patients with rheumatoid arthritis and other types of synovitis. J Rheumatol1996;23:10–5.</note>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>23</number>
</detail>
<extent unit="pages"><start>10</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R24"><titleInfo><title>Br J Rheumatol</title>
</titleInfo>
<note>de Bandt M, Meyer O, Haim T, Kahn MF. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis patients. Br J Rheumatol1996;35:38–43.</note>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>35</number>
</detail>
<extent unit="pages"><start>38</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R25"><titleInfo><title>Arthritis Rheum</title>
</titleInfo>
<note>Mustila A, Korpela M, Mustonen J et al. Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis. A marker of severe disease with associated nephropathy. Arthritis Rheum1997;40:710–7.</note>
<part><date>1997</date>
<detail type="volume"><caption>vol.</caption>
<number>40</number>
</detail>
<extent unit="pages"><start>710</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R26"><titleInfo><title>Arthritis Rheum</title>
</titleInfo>
<note>Fort JG, Cowchock FS, Abruzzo RL, Smith JB. Anticardiolipin antibodies in patients with rheumatic diseases. Arthritis Rheum1987;30:752–60.</note>
<part><date>1987</date>
<detail type="volume"><caption>vol.</caption>
<number>30</number>
</detail>
<extent unit="pages"><start>752</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R27"><titleInfo><title>Br J Rheumatol</title>
</titleInfo>
<note>Keane A, Woods R, Dowding V, Roden D, Barry C. Anticardiolipin antibodies in rheumatoid arthritis. Br J Rheumatol1987;26:346–50.</note>
<part><date>1987</date>
<detail type="volume"><caption>vol.</caption>
<number>26</number>
</detail>
<extent unit="pages"><start>346</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R28"><titleInfo><title>J Rheumatol</title>
</titleInfo>
<note>Buchanan RR, Wardlaw JR, Riglar AG, Little John GO, Miller MH. Antiphospholipid antibodies in the connective tissue diseases: their relation to the antiphospholipid syndrome and forme fruste disease. J Rheumatol1989;16:757–61.</note>
<part><date>1989</date>
<detail type="volume"><caption>vol.</caption>
<number>16</number>
</detail>
<extent unit="pages"><start>757</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R29"><titleInfo><title>Ann Rheum Dis</title>
</titleInfo>
<note>Seriolo B, Cutolo M, Fasciolo D, de Cesari F, Accardo S. Anticardiolipin antibodies in rheumatoid arthritis. Ann Rheum Dis1992;51:1100.</note>
<part><date>1992</date>
<detail type="volume"><caption>vol.</caption>
<number>51</number>
</detail>
<extent unit="pages"><start>1100</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R30"><titleInfo><title>Br J Dermatol</title>
</titleInfo>
<note>Wolf P, Gretler J, Aglas F, Auer‐Grumbach P, Rainer F. Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations. Br J Dermatol1994;131:48–51.</note>
<part><date>1994</date>
<detail type="volume"><caption>vol.</caption>
<number>131</number>
</detail>
<extent unit="pages"><start>48</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R31"><titleInfo><title>Am J Med</title>
</titleInfo>
<note>Merkel PA, Chang YC, Pierangeli SS, Convery K, Harris N, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med1996;101:576–83.</note>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>101</number>
</detail>
<extent unit="pages"><start>576</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R32"><titleInfo><title>Allergy</title>
</titleInfo>
<note>Wiik A. Granulocyte‐specific antinuclear antibodies. Allergy1980;35:263–89.</note>
<part><date>1980</date>
<detail type="volume"><caption>vol.</caption>
<number>35</number>
</detail>
<extent unit="pages"><start>263</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R33"><titleInfo><title>Int Arch Allergy Appl Immunol</title>
</titleInfo>
<note>Schnabel A, Hauschild S, Gross WL. Anti‐neutrophil cytoplasmic antibodies in generalized autoimmune diseases. Int Arch Allergy Appl Immunol1996;109:201–6.</note>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>109</number>
</detail>
<extent unit="pages"><start>201</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R34"><titleInfo><title>J Immunol Methods</title>
</titleInfo>
<note>Audrain MAP, Baranger AR, Lockwood CM, Esnault VLM. High immunoreactivity of lactoferrin contaminating commercially purified myeloperoxidase. J Immunol Methods1994;176:23–31.</note>
<part><date>1994</date>
<detail type="volume"><caption>vol.</caption>
<number>176</number>
</detail>
<extent unit="pages"><start>23</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R35"><titleInfo><title>Clin Exp Immunol</title>
</titleInfo>
<note>Brimnes J, Halberg P, Jacobsen S, Wiik A, Heegard NHH. Specificities of anti‐neutrophil antibodies in patients with rheumatoid arthritis (RA). Clin Exp Immunol1997;110:250–6.</note>
<part><date>1997</date>
<detail type="volume"><caption>vol.</caption>
<number>110</number>
</detail>
<extent unit="pages"><start>250</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R36"><titleInfo><title>Clin Exp Immunol</title>
</titleInfo>
<note>Savige JA, Gallichio MC, Stockman A, Cunningham TJ, Rowley MJ. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Clin Exp Immunol1991;86:92–8.</note>
<part><date>1991</date>
<detail type="volume"><caption>vol.</caption>
<number>86</number>
</detail>
<extent unit="pages"><start>92</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R37"><titleInfo><title>J Egyptian Public Health Assoc</title>
</titleInfo>
<note>Rabee SA, Sallam AM, Ayuoub NM, Kholy EE. Anticardiolipin antibodies in rheumatoid arthritis. J Egyptian Public Health Assoc1994;69:47–63.</note>
<part><date>1994</date>
<detail type="volume"><caption>vol.</caption>
<number>69</number>
</detail>
<extent unit="pages"><start>47</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R38"><titleInfo><title>J Rheumatol</title>
</titleInfo>
<note>Monteagudo M, Montalban J, Alvarez J, Lima J, Garcia‐Bragado F, Barquinero J. Stroke and anticardiolipin antibodies in a patient with rheumatoid arthritis and large granular lymphocyte proliferation. J Rheumatol1988;15:1589–90.</note>
<part><date>1988</date>
<detail type="volume"><caption>vol.</caption>
<number>15</number>
</detail>
<extent unit="pages"><start>1589</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R39"><titleInfo><title>J Rheumatol</title>
</titleInfo>
<note>Voisin L, Dérumeaux G, Borg JY et al. Catastrophic antiphospholipid syndrome with fatal acute course in rheumatoid arthritis. J Rheumatol1995;22:1586–8.</note>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>22</number>
</detail>
<extent unit="pages"><start>1586</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R40"><titleInfo><title>Thromb Haemostasis</title>
</titleInfo>
<note>Seriolo B, Accardo S, Fasciolo D, Sulli A, Bertolini D, Cutolo M. Lipoprotein (a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis. Thromb Haemostasis1995;74:799–800.</note>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>74</number>
</detail>
<extent unit="pages"><start>799</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R41"><titleInfo><title>Lupus</title>
</titleInfo>
<note>Kaburaki J, Kuwana M, Yamamoto M, Kawai S, Matsuura E, Ikeda Y. Disease distribution of beta 2‐glycoprotein 1‐dependent anticardiolipin antibodies in rheumatic diseases. Lupus1995;4:27S–31S.</note>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>4</number>
</detail>
<extent unit="pages"><start>27S</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R42"><titleInfo><title>J Immunol</title>
</titleInfo>
<note>Monestier M, Kandiah DA, Kouts S et al. Monoclonal antibodies from NZW × BXSB F1 mice to β2‐glycoprotein 1 and cardiolipin. J Immunol1996;156:2631–41.</note>
<part><date>1996</date>
<detail type="volume"><caption>vol.</caption>
<number>156</number>
</detail>
<extent unit="pages"><start>2631</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R43"><titleInfo><title>J Immunol</title>
</titleInfo>
<note>Hashimoto Y, Kawamura M, Ichkawa K et al. Anticardiolipin antibodies in NZW × BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol1992;149:1063–8.</note>
<part><date>1992</date>
<detail type="volume"><caption>vol.</caption>
<number>149</number>
</detail>
<extent unit="pages"><start>1063</start>
</extent>
</part>
</relatedItem>
<relatedItem type="references" displayLabel="R44"><titleInfo><title>Clin Exp Immunol</title>
</titleInfo>
<note>Finnern R, Bye JM, Dolman KM et al. Molecular characteristics of anti‐self antibody fragments against neutrophil cytoplasmic antigens from human V gene phage display libraries. Clin Exp Immunol1995;102:566–74.</note>
<part><date>1995</date>
<detail type="volume"><caption>vol.</caption>
<number>102</number>
</detail>
<extent unit="pages"><start>566</start>
</extent>
</part>
</relatedItem>
<identifier type="istex">0A72297B4B08314DD6A093A83221189C1CDE470D</identifier>
<identifier type="ark">ark:/67375/HXZ-89VBC27C-0</identifier>
<identifier type="DOI">10.1093/rheumatology/39.5.481</identifier>
<identifier type="PII">1460-2172</identifier>
<identifier type="local">0390481</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© British Society for Rheumatology</accessCondition>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-GTWS0RDP-M">oup</recordContentSource>
<recordOrigin>Converted from  (version 1.2.0) to MODS version 3.6.</recordOrigin>
<recordCreationDate encoding="w3cdtf">2019-12-09</recordCreationDate>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/HXZ-89VBC27C-0/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001895 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001895 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:0A72297B4B08314DD6A093A83221189C1CDE470D
   |texte=   Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis

Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri